These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9556644)

  • 1. Calcium channel antagonists: morbidity and mortality--what's the evidence?
    Straka RJ; Swanson AL; Parra D
    Am Fam Physician; 1998 Apr; 57(7):1551-60. PubMed ID: 9556644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Calcium antagonists--much noise about nothing?].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1995 Dec; 18(12):344-9. PubMed ID: 8569586
    [No Abstract]   [Full Text] [Related]  

  • 4. [Controversy about using calcium antagonists for treatment of coronary disease and hypertension].
    Głuszek J; Pawlaczyk-Gabriel K
    Przegl Lek; 1997; 54(9):597-601. PubMed ID: 9501678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the nurses' health study.
    Michels KB; Rosner BA; Walker AM; Stampfer MJ; Manson JE; Colditz GA; Hennekens CH; Willett WC
    Cancer; 1998 Nov; 83(9):2003-7. PubMed ID: 9806660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of calcium-channel blockers.
    Massie BM
    Clin Cardiol; 1998 Dec; 21(12 Suppl 2):II12-7. PubMed ID: 9853194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of calcium channel blockers as antihypertensives in relation to mortality and cancer incidence: a population-based observational study.
    Lindberg G; Lindblad U; Löw-Larsen B; Merlo J; Melander A; Råstam L
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):493-7. PubMed ID: 12426934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of hypertension with calcium antagonists and increased risk of acute myocardial infarction: reliable results?].
    Jensen G
    Ugeskr Laeger; 1995 Oct; 157(41):5732. PubMed ID: 7571114
    [No Abstract]   [Full Text] [Related]  

  • 10. Nifedipine trials.
    Rafflenbeul W
    Circulation; 1996 Apr; 93(7):1473-4. PubMed ID: 8641042
    [No Abstract]   [Full Text] [Related]  

  • 11. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL; Baker WL; White CM
    Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nifedipine in patients with heart disease.
    Phillips RA; Krakoff LR
    Circulation; 1996 Apr; 93(7):1474-5. PubMed ID: 8641043
    [No Abstract]   [Full Text] [Related]  

  • 13. [Influence of risk factors and pharmacological treatment on mortality in patients with essential hypertension].
    Román O; Cuevas G; Bunout D
    Rev Med Chil; 1998 Jul; 126(7):745-52. PubMed ID: 9830766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged QT interval and ventricular fibrillation after treatment with sublingual nifedipine for malignant hypertension.
    Peters FP; de Zwaan C; Kho L
    Arch Intern Med; 1997 Dec 8-22; 157(22):2665-6. PubMed ID: 9531240
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
    Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C
    Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Calcium antagonists: safe or unsafe?].
    Rosendaal FR; Psaty BM; Furberg CD
    Ned Tijdschr Geneeskd; 1996 Apr; 140(17):916-8. PubMed ID: 8676969
    [No Abstract]   [Full Text] [Related]  

  • 18. Calcium channel blockers in the dock: innocent or guilty?
    Mackay JA; Sever PS
    J Hum Hypertens; 1996 May; 10(5):277-80. PubMed ID: 8817399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Which calcium antagonists for hypertension?].
    Degaute JP
    Rev Med Brux; 1998 Sep; 19(4):A389-92. PubMed ID: 9805980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension.
    Hypertens Res; 1997 Jun; 20(2):61-73. PubMed ID: 9220269
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.